What is the appropriate evaluation and management for a patient with a bilateral lower extremity non‑blanching purpuric rash?

Bilateral Lower Extremity Non-Blanching Purpuric Rash: Evaluation and Management

Obtain a skin biopsy immediately to establish the diagnosis of vasculitis, as this is strongly supportive and essential for guiding treatment decisions 1. The non-blanching purpuric rash suggests cutaneous small-vessel vasculitis, and histopathologic confirmation is critical before initiating immunosuppressive therapy.

Diagnostic Workup Algorithm

Immediate Clinical Assessment

Look for these specific features during examination:

• Palpability of the purpura (suggests leukocytoclastic vasculitis) 2
• Distribution pattern (bilateral lower extremities is classic for IgA vasculitis and drug-induced vasculitis) 3, 4
• Associated symptoms: Joint pain/swelling (ankles, hands, wrists), abdominal pain, or edema 3, 5
• Systemic involvement: Check for fever, renal symptoms (hematuria, proteinuria), or respiratory symptoms 1

Essential Laboratory Investigations

Order these tests concurrently with biopsy:

• Urinalysis with microscopy (hematuria and proteinuria indicate renal involvement requiring urgent intervention) 3
• Serum creatinine (if ≥500 μmol/L or 5.7 mg/dL, plasma exchange should be considered) 1
• ANCA testing (for ANCA-associated vasculitis, though clinical assessment should guide treatment decisions, not ANCA alone) 1
• Cryoglobulins (if hepatitis C history or concern for cryoglobulinemic vasculitis) 4
• Complete blood count, inflammatory markers (CRP, ESR)
• Hepatitis B and C serology

Medication History Review

Critical: Identify any recent medication exposures within the past 2-4 weeks:

• Antibiotics (especially trimethoprim-sulfamethoxazole, vancomycin) 6, 4
• Allopurinol 7
• Biologics (infliximab, other TNF inhibitors) 8
• Drug-induced vasculitis is a common identifiable cause and requires immediate cessation of the offending agent 2, 4

Infectious Workup

• Sexual history and NAAT testing for gonorrhea/chlamydia if sexually active (disseminated gonococcal infection can present with purpuric rash and arthritis) 9
• Blood cultures if febrile or systemically unwell
• Consider meningococcal disease if rapid deterioration with shock 10

Management Based on Severity

Non-Organ-Threatening Disease

If skin-limited without renal, pulmonary, or severe systemic involvement:

• Discontinue any potential offending medications immediately 4, 8
• Many cases are self-limited and resolve spontaneously 2
• If treatment needed: Oral prednisone 0.5-1 mg/kg daily with slow taper 3
• Alternative agents: dapsone or colchicine for refractory cutaneous disease 2

Organ-Threatening or Life-Threatening Disease

If renal involvement (proteinuria, hematuria, elevated creatinine) or other organ involvement:

For ANCA-associated vasculitis (GPA/MPA):

• Glucocorticoids PLUS either cyclophosphamide OR rituximab (Grade A recommendation) 1
• Add plasma exchange if serum creatinine ≥500 μmol/L (5.7 mg/dL) due to rapidly progressive glomerulonephritis (Grade B recommendation) 1

For IgA vasculitis with nephritis:

• Oral prednisone 1 mg/kg daily (typically 60-80 mg) for 7 days, then slow taper over weeks 3
• Add ACE inhibitor (lisinopril 2.5-10 mg daily) for proteinuria 3
• Loop diuretic if significant edema 3

Refractory Disease

• Switch immunosuppressive agents (cyclophosphamide to rituximab or vice versa) 1
• Transfer to expert vasculitis center for further evaluation and potential clinical trial enrollment 1

Critical Pitfalls to Avoid

1. Do not delay skin biopsy - it is the cornerstone of diagnosis and strongly recommended even in suspected relapsing disease 1

2. Do not rely on ANCA testing alone to guide treatment changes; use structured clinical assessment 1

3. Do not miss drug-induced vasculitis - always obtain detailed medication history including recent antibiotic courses, as cessation of the offending agent leads to resolution 4, 8

4. Do not overlook renal involvement - check urinalysis in all patients, as renal disease significantly changes management and prognosis 1, 3

5. Do not assume benign course in adults - while IgA vasculitis is common in children, adult presentations have more severe systemic manifestations and complications 5

6. Do not miss disseminated gonococcal infection in sexually active patients with purpura and arthritis - this requires 7 days of parenteral ceftriaxone 9

Follow-Up and Maintenance

• Continue remission-maintenance therapy for at least 24 months after achieving sustained remission in ANCA-associated vasculitis 1
• Maintenance options: low-dose glucocorticoids plus azathioprine, rituximab, methotrexate, or mycophenolate mofetil 1
• Monitor for relapse with regular clinical assessment, urinalysis, and renal function